3-Phenyl-2-[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-1,6-Naphthyridin-5(6H)-one;Akti_2008;Akt1 and Akt2-IN-1;3-phenyl-2-(4-((4-(5-(pyridin-2-yl)-1H-1,2,4-triazol-3-yl)piperidin-1-yl)methyl)phenyl)-1,6-naphthyridin-5(6H)-one;Akt1Akt2-IN-17;Akt1/2 inhibitor 1;1,6-Naphthyridin-5(6H)-one, 3-phenyl-2-[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-;Akt-1 and Akt2-IN-1,Akt1 and Akt2IN1,Akt1 and Akt2 IN 1
Akt1 and Akt2-IN-1 is used as a potent and selective allosteric inhibitor of Akt1 and Akt2 for research purposes; it demonstrates in vivo efficacy in inhibiting tumor growth (e.g., A2780 xenografts) as monotherapy; it achieves high levels of Akt1/2 inhibition in vivo (e.g., in mouse lung); and it is employed to study Akt signaling pathways due to its selectivity over Akt3 and other AGC family kinases.